Find a Doctor

Jurgen Sota

University Of Siena
Male

Bio


Jurgen Sota is in Siena, Italy. They have been an author on 51 peer reviewed articles in the past 15 years.

Contact

Siena, IT

Latest Research


Latest Advance
Study
  • Condition: Scleritis
  • Journal: Mediators of inflammation
  • Treatment Used: Biologic Agents (Rituximab, Anakinra, Tocilizumab, Tofacitinib, and Abatacept)
  • Number of Patients: 14
  • Published —
In this study, researchers evaluated the safety and effectiveness of biologic agents (rituximab, anakinra, tocilizumab, tofacitinib, and abatacept) for the treatment of scleritis.
Latest Advance
Study
  • Condition: Axial Spondyloarthritis
  • Journal: Mediators of inflammation
  • Treatment Used: Secukinumab
  • Number of Patients: 39
  • Published —
This study tested the safety and efficacy of using secukinumab to treat patients with axial spondyloarthritis.
Latest Advance
Study
  • Condition: Uveitic Macular Edema
  • Journal: Clinical and experimental rheumatology
  • Treatment Used: Monoclonal Anti-Tumor Necrosis Factor (TNF)-? Antibodies
  • Number of Patients: 36
  • Published —
This study assessed the effectiveness of anti-tumor necrosis factor (TNF)-? agents in the treatment of refractory uveitic macular edema (swelling; UME).
Latest Advance
Study
  • Condition: Non-infectious Uveitis
  • Journal: Clinical and experimental rheumatology
  • Treatment Used: Certolizumab Pegol and Golimumab
  • Number of Patients: 21
  • Published —
In this study, researchers evaluated the effectiveness of using either certolizumab pegol or golimumab for the treatment of non-infectious uveitis.
Latest Advance
Study
  • Condition: Non-infectious anterior uveitis
  • Journal: Clinical and experimental rheumatology
  • Treatment Used: Anti-tumour necrosis factor-? monoclonal antibodies
  • Number of Patients: 69
  • Published —
The study researched the outcomes of anti-tumour necrosis factor-? monoclonal antibodies for non-infectious anterior uveitis.
Latest Advance
Study
  • Condition: Non-infectious intermediate uveitis, posterior uveitis, and panuveitis
  • Journal: Clinical rheumatology
  • Treatment Used: Adalimumab and infliximab i
  • Number of Patients: 107
  • Published —
This study evaluated the efficacy of adalimumab (ADA) and infliximab (IFX) in patients with non-infectious intermediate uveitis, posterior uveitis, and panuveitis after a 12-month follow-up.
Latest Advance
Study
  • Condition: Recalcitrant Retinal Vasculitis
  • Journal: Clinical rheumatology
  • Treatment Used: Adalimumab (ADA) and Infliximab (IFX)
  • Number of Patients: 48
  • Published —
This study evaluated the effectiveness of tumor necrosis factor (TNF)-? blockers adalimumab (ADA) and infliximab (IFX) in refractory sight-threatening retinal vasculitis (RV) during a 12-month follow-up period.

Clinical Trials


This doctor has not participated in any recent clinical trials.

All Publications
View All


Publication
Study
  • Journal: Expert review of clinical immunology
  • Published —
The current status of biological treatment for uveitis.

Contact

Siena, IT

Insurance

Contact them to find out if they accept your insurance plan.